Niagen Bioscience
NAGE
77 hedge funds and large institutions have $61.4M invested in Niagen Bioscience in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
17% more funds holding
Funds holding: 66 → 77 (+11)
1.82% more ownership
Funds ownership: 23.01% → 24.83% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $64.9M → $61.4M (-$3.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SA
Sycale Advisors
New York
|
+$1.02M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$983K |
| 3 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$835K |
| 4 |
Morgan Stanley
New York
|
+$829K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$681K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$621K |
| 2 |
Bessemer Group
Woodbridge,
New Jersey
|
-$532K |
| 3 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$387K |
| 4 |
Two Sigma Investments
New York
|
-$324K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$247K |
NAGE Hedge Fund Activity: Q3 2020 in Review
77 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q3 2020, worth a combined $61.4M — down 5.5% from $64.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new NAGE positions and 5 closed out — a net gain of 11 holders — while 24 added to existing stakes and 20 trimmed.
The largest buyer was Sycale Advisors, adding an estimated $1.02M. The largest seller was Renaissance Technologies, cutting an estimated $621K.
- 77 institutional investors held Niagen Bioscience (NAGE) as of Q3 2020, up from 66 in Q2 2020.
- Funds reported $61.4M of Niagen Bioscience stock for Q3 2020, down 5.5% quarter-over-quarter.
- 16 funds opened new Niagen Bioscience positions in Q3 2020 and 5 closed out, a net change of +11 holders.
- The largest Niagen Bioscience buyer in Q3 2020 was Sycale Advisors, an estimated $1.02M added.
- The largest Niagen Bioscience seller in Q3 2020 was Renaissance Technologies, an estimated $621K sold.
Based on aggregated 13F filings for Q3 2020.